Key takeaways
- The small, short-term sleep studies reviewed here have direct Ajinomoto author ties. They do not establish a dependable benefit for a generic glycine product (Original subjective-sleep abstract; Original PSG trial; Original restriction trial).
- The familiar 3 g bedtime amount is a research protocol, not a proven optimum or a recommendation for everyone (Bedtime protocol; Restriction protocol).
- Faster entry into slow-wave sleep is different from more deep sleep, longer sleep or successful treatment of chronic insomnia (Original PSG results).
- The reviewed sleep pilots do not establish treatment of anxiety or depression, stress relief from glycine alone, or that people can safely need less sleep (Review scope and limitations; Partial sleep restriction).
- Free glycine, magnesium glycinate, collagen and glycine combined with another active ingredient are different interventions. A result for one does not establish the others’ sleep benefit (Ingredient and protein context; Review excludes combinations and derivatives).
- Short studies cannot settle long-term safety, medicine combinations, pregnancy or use in children (Safety evidence gaps).
Evidence verdict: Insufficient for a dependable sleep or stress benefit in the evidence reviewed here. Some commercially linked pilots reported favorable outcomes, but tiny samples, short follow-up and incomplete original access limit the estimate. Confidence is moderate in this assessment of the reviewed evidence, and low in a precise benefit or long-term harm estimate. Company ties and method limitations are assessed separately; uncertain benefit does not mean proven ineffectiveness. Original PSG trial; Original restriction trial; Systematic review.
The relevant question is whether swallowing extra free glycine improves a person’s sleep or functioning beyond a suitable control. Its normal role in the body cannot answer that question. A supplement can contain a familiar nutrient and still need good clinical trials for a particular advertised use. The most useful reading of the current literature is a promising research lead with substantial uncertainty, rather than an established treatment (Clinical review limitations).
Contents
Evidence summary · What it is · Forms · Mechanism · Hype · Benefits · Verdicts · Risks · Interactions · Who should avoid · Studied doses · Laboratory evidence · Money and countries · Regulation · FAQs · Sources and scorecard
Evidence summary
Reported company-linked studies remain visible as clinical context. The strict independence grade excludes evidence with direct commercial involvement and does not treat unknown funding as independent. Funding status does not by itself establish whether an outcome is true. The clinical methods and results are also examined. Original methods and declarations; Review bias assessment.
| Claim | Human evidence located | Funding and provenance | Independent strength |
|---|---|---|---|
| Better subjective sleep or next-morning feelings | Inagawa 2006: selected next-morning subjective outcomes favored 3 g; full original methods unavailable | Four Ajinomoto-affiliated authors; exact cash and procurement unresolved | Insufficient |
| Faster sleep or slow-wave-sleep onset | Yamadera 2007: 11 adults; two nights per condition, with only the second analyzed | Three Ajinomoto-affiliated authors; complete original main has no separate cash/supply statement | Insufficient (Complete original). |
| Daytime function after shortened sleep | Bannai 2012: seven analyzed men; day-one fatigue and selected vigilance results favored treatment | Three company-affiliated authors; employee participants; partial PROBRAIN support | Insufficient |
| Clinical insomnia, anxiety or depression treatment | The reviewed sleep pilots do not establish disease-specific remission or sustained treatment benefit | No adequate independently funded treatment evidence established in this reviewed set | Insufficient (Review limitations; Sleep pilot; Restriction pilot). |
| New athlete protocol | UMIN000058138: target 30 men; June 2026 record lists results as unpublished | Waseda sponsor; Ajinomoto explicitly named funder; amounts and supply terms unknown | No published efficacy conclusion in registry |
| Indefinite nightly safety | Seven-day exposure study and 2016 risk assessment have narrow scopes | Company-authored human study; public assessment partly relies on company-affiliated rat study | Long-term safety not established |
What glycine is
Glycine is an amino acid used in proteins and metabolism; the body also makes it. Protein-containing foods provide it. “Non-essential” is a nutritional classification about synthesis, not a statement that it is unimportant. The Norwegian Scientific Committee's assessment describes its physiological role, dietary occurrence and substantial uncertainty about supplemental safety thresholds.
This review concerns oral free glycine marketed for sleep or stress. It does not grade high-dose psychiatric adjunct treatment, treatment of inherited metabolic diseases, intravenous preparations, surgical irrigation, or glycine combined with other active substances. Those settings involve different exposures and clinical questions. A result elsewhere cannot be borrowed to make a bedtime powder look better tested (Route and combination eligibility).
Forms and grades
| Form or label | What changes | Evidence boundary |
|---|---|---|
| Free glycine powder, granules or capsules | Amount of glycine, excipients and delivery format | Closest to the isolated-ingredient question; powder and capsule equivalence is not established by a label alone (Tested granules and comparator; Tested flavored preparations). |
| Flavored glycine research preparation | Matching flavor and appearance can influence blinding | Research findings belong to the preparation and protocol tested (Tested granules and comparator; Tested flavored preparations). |
| Glycine plus GABA or other sleep ingredients | More than one active ingredient | A positive mixture result cannot identify glycine’s contribution (Glycine–GABA label). |
| Magnesium glycinate or bisglycinate | A magnesium-containing compound | Magnesium amount is not the same measurement as free-glycine amount; do not apply a 3 g glycine protocol to a magnesium label (Intervention exclusions; Glycine and protein context). |
| Collagen or gelatin | A protein source supplying multiple amino acids | Not an interchangeable dose of isolated glycine (Intervention exclusions; Glycine and protein context). |
| GlyNAC | Glycine plus N-acetylcysteine | Combination findings do not establish glycine-only sleep efficacy (Intervention exclusions; Glycine and protein context). |
| “Pharmaceutical,” “premium” or “clinical” grade | A claim about a product or its manufacture | Purity and identity are separate questions from clinical effectiveness (Intervention exclusions; Glycine and protein context). |
The boundaries above are analytical distinctions, not comparative product recommendations. A fair head-to-head trial would be needed to claim that one retail delivery form produces better sleep than another. The current Glyna product page illustrates why names alone are insufficient: it presents both glycine sleep products and glycine–GABA sleep-and-stress products, assigning the stress claims to GABA. That marketing distinction must not be rewritten as proof that glycine treats stress.
How it might work
Glycine participates in inhibitory signaling at glycine receptors and acts as a co-agonist at NMDA receptors. These roles do not predict the benefit of a swallowed retail dose. Bannai and Kawai’s company-authored pharmacology minireview summarizes mechanisms and earlier pilots; it is not an independently funded replication. Review identity; Complete original minireview.
The proposed sleep pathway includes thermoregulation and the suprachiasmatic nucleus. Kawai’s rodent experiments used oral 2 g/kg, receptor antagonists, brain microinjections and SCN lesions. They support a rat mechanism, not the size of a human benefit, clinical phase resetting, tolerance or chronic-insomnia remission. The authors explicitly report Ajinomoto funding for three academic collaborators and employment ties for four authors. Rodent article; Original methods and disclosures.
A mechanism also does not identify a deficiency. Poor sleep alone is not evidence that someone lacks glycine, and this literature does not validate a consumer blood test or symptom checklist for selecting likely responders (Review scope and limits).
Hype versus evidence
“More deep sleep” can mean reaching a stage sooner, spending more minutes in it, increasing its percentage, or feeling more refreshed. Those outcomes differ. Yamadera’s pilot found earlier sleep and slow-wave-sleep onset with unchanged stage proportions; one representative hypnogram does not establish a consistent increase in deep-sleep quantity. Yamadera identity; Full original results.
Similarly, a favorable reaction-time test is not evidence that it is safe to drive after inadequate sleep. An acute sleep-restriction experiment does not establish that sleep can be compressed without consequences. No practical “sleep replacement” claim follows from the studies reviewed (Restriction experiment and outcome limits).
“Natural,” “non-hormonal” and “made by your body” describe origin or identity. None supplies missing long-term trials. “Clinically studied” can mean that an ingredient appeared in a small pilot; it does not tell readers whether the design was blinded, the main endpoint succeeded, the benefit mattered to patients, or an independent group replicated it (Risk of bias; Consumer evidence cautions).
Benefits by claim
Occasional sleep dissatisfaction — Insufficient independent evidence
The early double-blind crossover abstract reports favorable fatigue, liveliness and clear-headedness the next morning after 3 g before bedtime. Four authors have Ajinomoto affiliations. Full original methods and numerical results remain unavailable here, and the retrieved reviews disagree on participant count: VKM reports 15, while the company minireview and Soh review report 19. No count is certified from the original. Original abstract; VKM account; Company review account.
The later PSG study included 11 daytime-working adults aged 30–57 with sleep dissatisfaction. It was a randomized single-blind crossover; only the second of two nights per condition entered the results. Sleep-onset latency and slow-wave-sleep-onset latency favored glycine, but stage proportions were unchanged. Overall sleepiness tests were borderline (p=0.058 and p=0.056), with isolated favorable post hoc time points. A small short trial with many comparisons does not settle a clinically important, all-day benefit. Full original methods and results.
Daytime tiredness after short sleep — Insufficient independent evidence
Bannai’s randomized single-blind crossover used 3 g 30 minutes before bed for three nights with time in bed restricted by 25%. Ten healthy male employees enrolled; seven were analyzed after one dropout and two medication exclusions. Day-one fatigue favored glycine (p=0.022), but day-three subjective outcomes and the fatigue questionnaire were not significantly different. Vigilance reaction time favored treatment on the reported test days; most other performance measures did not. Bannai 2012; Complete original tables.
This is hypothesis-generating. The sample cannot tell us whether a benefit persists in shift workers, people with chronic insomnia, women, older adults with multiple illnesses or people taking sedating medicines. Excluding participants after enrollment also makes it important to inspect the full analysis rather than repeating an enrollment number as if it were the number providing evidence (Original exclusions and population).
Chronic insomnia — Insufficient
The studies above do not establish sustained remission, a meaningful response rate or superiority to established treatment. For persistent insomnia, the US National Heart, Lung, and Blood Institute identifies cognitive behavioral therapy for insomnia as the usual first treatment option. That guidance is clinical context, not a head-to-head glycine comparison.
A supplement experiment should not postpone assessment of recurrent sleeplessness, loud snoring with breathing pauses, or disabling daytime sleepiness. Treatment depends on the cause; an ingredient cannot be assumed to address every reason someone sleeps poorly (Clinical assessment and treatment context).
Stress, anxiety and depression — Insufficient
The reviewed sleep studies do not establish anxiety-disorder treatment, depression remission or stress relief from glycine alone. The broad review includes different clinical populations, routes and much higher doses; its positive psychiatric findings cannot be transferred to ordinary stress or self-treatment. Clinical review scope and limitations.
Circadian rhythm, jet lag and athletic recovery — Insufficient
A rat theory involving a circadian brain structure does not establish useful human phase resetting. UMIN000058138 targets 30 male Waseda athletes in a randomized double-blind crossover. Its June 2026 record names Ajinomoto as funder, says no longer recruiting and lists results as unpublished. Target enrollment and registration do not establish efficacy. Rat mechanism; Fresh trial record.
What systematic reviews add
Soh’s review was published online in 2023 and in a 2024 issue. It searched through April 2022 and describes the small healthy-population sleep studies as high risk of bias. It could not pool outcomes, and classified a study as positive when at least one pre–post or controlled outcome was significant. That method does not establish a precise clinical effect. The full original main declares no conflicts and has no separate project-funding statement. A current institutional profile verifies Andrea Maier’s broader longevity-clinic founder roles; no glycine-review funding link to those clinics is established. Review; Original methods and declarations; Institutional biography.
What works and what has not been established
| Reader's question | Verdict | What would change the assessment? |
|---|---|---|
| Is there any human signal worth studying? | Yes, in small commercially linked experiments | Independent, preregistered replication (Small PSG trial; Restriction trial). |
| Is a dependable sleep benefit independently established? | Not in the evidence reviewed here | Adequately powered trials with transparent procurement, blinding and clinically meaningful endpoints (Bias and replication limits). |
| Is it established treatment for chronic insomnia? | No | Sustained disease-specific outcomes and comparison with appropriate care (Insomnia care; Review limits). |
| Can it replace sleep, anxiety care or antidepressants? | The studies reviewed here do not support that use | These claims require their own direct clinical evidence (Outcome boundaries; Clinical scope). |
| Are all glycine-containing products equivalent? | No basis for assuming equivalence | Formulation-specific testing (Excluded combinations/derivatives). |
| Has long-term nightly safety been settled? | No | Longer systematic adverse-event follow-up in relevant groups (Safety gaps). |
Negative table verdicts describe the evidence reviewed here, not a claim that every possible future experiment must be negative.
Risks and side effects
| Issue | What is actually supported | Practical boundary |
|---|---|---|
| Digestive discomfort | A 12-person open study reported possible glycine-related soft stool or abdominal pain in three participants during bedtime 9 g dosing | Short-term findings do not establish an incidence rate or a safe upper limit (Acute-study identity; Original methods and adverse events). |
| Next-day impairment | Small short-term experiments did not settle safety in complex real-world situations | Feeling alert is not proof of unimpaired driving (Selected cognitive outcomes; Selected performance outcomes). |
| Long-term use | The sleep studies are far shorter than months or years of use | Absence of observed harm in a pilot is not a long-term safety guarantee (Long-term data gaps; Seven-day exposure). |
| Pregnancy, breastfeeding and children | Relevant sleep-treatment safety evidence was not established in this review | No routine self-treatment recommendation follows (Population and dose limits; Professional review). |
| Kidney, liver or metabolic disease | Healthy-volunteer results are not sufficient for these groups | The clinical team should assess the entire product and condition (Population and dose limits; Professional review). |
| Mixtures and excipients | The label may include other active ingredients and allergens | Attribute risks to the complete preparation, not only glycine (Complete product labels; Combination cautions). |
The 12-person acute study used 9 g/day for seven days in an open sequence, with only the last three days at bedtime. It cannot establish a general safe upper limit or long-term incidence. VKM considered specified supplemental doses of 20–650 mg/day unlikely to cause harm in people aged 10 and older, using a four-week rat study and an uncertainty factor. It did not assess the 3 g bedtime protocol and found inadequate human safety data. Its rat-derived comparison value is not a human upper intake limit; the underlying company-affiliated study also discusses unresolved longer-duration animal findings. Human study; Assessment; Rat-study identity; Original toxicology and procurement.
For inherited nonketotic hyperglycinemia, excess glycine accumulates in tissues and can disrupt brain function. This is a specialist-care setting, not a reason to experiment with an added glycine supplement. MedlinePlus Genetics
Interactions and important unknowns
| Medicine or exposure | Evidence level | Interpretation |
|---|---|---|
| Clozapine | Small high-dose psychiatric adjunct trial, with only partial original sections retrieved | At 60 g/day no added clinical/cognitive benefit was detected. One recipient stopped all medicines and required hospitalization; a contribution from glycine could not be ruled out. This does not establish the effect or safety of a bedtime dose (Original trial record). |
| Other psychiatric medicines, ketamine or NMDA-active treatments | Pharmacological relevance; useful glycine-specific combination data not established here | Do not predict the clinical interaction solely from a receptor diagram (Receptor context; Different clinical combination). |
| Sedatives, alcohol or multi-ingredient sleep products | No adequate direct glycine-specific interaction trials located | Absence of a documented interaction is not confirmation that stacking is safe (Interaction evidence gap; Combination precautions). |
| Glucose- or blood-pressure-lowering medicines | No dependable sleep-dose interaction estimate established here | Do not invent an interaction magnitude from unrelated metabolic experiments (Dose/population differences; Interaction evidence gap). |
| Other glycine-containing supplements | Total exposure may be unclear | Review the complete ingredient list and duplicate ingredients (Complete-label precautions). |
Evins’s schizophrenia trial used 60 g/day for eight weeks alongside unchanged clozapine, after a placebo lead-in. Original indexed methods/results describe 27 analyzed patients and no significant clinical or cognitive advantage. A hospitalization after stopping all medications illustrates why “no clinically significant worsening of ratings” is not proof that nothing concerning occurred. The complete final paper and financial footnotes remain unavailable; cash funders and product procurement are unresolved. This is context, not bedtime-dose efficacy or combination-safety evidence. PubMed original abstract; Publisher original sections.
This is a list of relevant issues and gaps, not a claim to list every possible interaction. A pharmacist can review the exact product, dose and medication list. Do not stop a prescribed treatment to accommodate a supplement (Medicine and supplement guidance).
Who should avoid self-treatment
- People with known disorders of glycine metabolism should follow their specialist’s plan (Inherited metabolic disorder).
- Children, pregnant or breastfeeding people, and people with substantial kidney or liver disease should not infer safety from these adult sleep pilots (Age/dose/safety gaps; Professional review).
- People taking clozapine or other psychiatric medicines should involve the prescribing clinician before adding glycine (Different psychiatric protocol; Prescriber review).
- People with persistent insomnia, suspected sleep apnea or disabling daytime sleepiness need assessment rather than a supplement-only plan (Persistent insomnia care).
- Anyone who develops a concerning reaction should stop the supplement and seek appropriate care; severe breathing difficulty or collapse requires emergency help (Stop and seek care after a reaction; Emergency symptoms).
These boundaries combine direct disease-specific evidence with explicit precaution where data are missing. They are not all demonstrated glycine contraindications. The FDA's consumer guidance stresses that supplement combinations and medicine use require attention and that adverse reactions should be reported.
Studied doses, not personal dosing instructions
| Research setting | Protocol | Duration or population boundary |
|---|---|---|
| Subjective-sleep pilot | 3 g before bedtime | Full original methods not retrieved; do not treat secondary sample counts as verified (Original abstract). |
| PSG pilot | 3 g granules within one hour before bed | 11 adults, two nights per condition; first night excluded for acclimatization (Pilot identity; Full original methods). |
| Partial sleep restriction | 3 g 30 minutes before bed | Three nights per condition; seven analyzed men (Original analyzed population). |
| Acute tolerability | 9 g/day for seven days: divided after meals, daytime bolus, then three bedtime doses | 12 healthy volunteers in an open fixed sequence; not a human upper intake limit (Study identity; Full original protocol). |
| Clozapine adjunct experiment | 60 g/day | Psychiatric research; no basis for copying this into a sleep protocol (Original psychiatric protocol). |
Protocols are sourced to Inagawa, Yamadera, Bannai, acute tolerability research and Evins.
The repetition of an amount across related experiments does not establish a dose–response curve. These studies do not demonstrate that 1 g is ineffective, 3 g is optimal, 5 g is superior, or cycling is necessary. Timing recommendations more precise than the protocols would add certainty the evidence does not supply (Tested protocol; Tested protocol).
Animal and laboratory evidence stays separate
The rodent NMDA/temperature experiments examine mechanism; the four-week rat study examines toxicology. Neither measures sleep benefit or long-term safety in people. The mechanism paper explicitly discloses Ajinomoto-funded academic collaborators and employees. The toxicology paper lists only Ajinomoto Pharmaceuticals authors but states that the glycine was purchased from Nacalai Tesque; it declares no actual or potential conflicts. Supplier identity, company employment and unreported cash allocation are separate facts. Mechanism identity; Original mechanism declarations; Toxicology identity; Original purchased material and COI.
A plausible explanation can guide a trial. It cannot replace one. This review does not use animal temperature changes, receptor activity or biochemical markers to upgrade its human efficacy verdict (Animal-to-human inference boundary; Human review limitations).
Follow the money, countries and backers
Research funding at a glance
23 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The commercial subject
Glycine is a general chemical ingredient rather than one company's property. Ajinomoto is especially relevant because its employees appear in the key sleep literature and it sells Glyna. Its corporate profile places its headquarters in Tokyo, Japan. Its product page establishes a direct sales interest. Other bulk suppliers and retail brands can also benefit when demand rises; this review did not audit every seller or its owners.
The fresh shareholder page is expressly dated 30 September 2025 and lists trust/custody banks and insurers among the major registered holders. This is a dated ownership record; no current percentage is asserted. A nominee account is not proof of its ultimate beneficial owners or control over a study conclusion. Dated registered holdings.
Manufacturing country is a separate question. A 2020 company announcement identifies Glyna among products made at the Mie facility in Japan. This historical plant disclosure does not verify the origin of every present retail batch or its raw glycine. Obtain batch-specific documentation before making a country-of-manufacture claim about a different product.
Research and public evidence
The three early sleep papers have company author affiliations. Bannai’s generic no-conflicts declaration does not erase its employee recruitment, company IRB or three company-affiliated authors. Partial PROBRAIN support does not establish wholly public financing. The report does not apportion cash or human-product transactions between the public program and company. Original early abstract/affiliations; Complete PSG report; Restriction-study methods and declarations.
The review authors’ NUS/NUHS and VU affiliations are separate from its trial evidence. The full review declares no conflicts and has no separate project-funding statement. Current NUHS biography text identifies Maier as Chi Longevity co-founder and documents its founding in 2022; it also lists a later Netherlands clinic. These are broader commercial roles, not proof that either clinic funded this review, supplied glycine or affected its conclusion. Review declarations; Current institutional biography.
VKM’s governance page describes its scientific committee, published conflict-management process and public-health-institute administrative hosting. That institutional description does not clear all historic individual interests or the industry-origin rat input. FDA’s FY2026 plan separately identifies budget authority and regulated-program user fees. NHLBI describes its budget as primarily congressional appropriations. These are institutional finance facts, not evidence that glycine sellers funded particular guidance or that any agency tested glycine efficacy. VKM governance; FDA FY2026 plan; NHLBI budget provenance.
Documented relationship map

The accompanying funding graphic is a map of disclosed relationships, not a suggestion of hidden control. Its equivalent text is:
- Ajinomoto, Japan → company affiliations in the early human sleep papers (Company affiliations; Company affiliations; Company affiliations).
- Ajinomoto, Japan → seller of Glyna (Seller and product).
- Ajinomoto, Japan → named funder of the Waseda athlete trial (Named funder).
- PROBRAIN program → partial support acknowledged in Bannai 2012; amount and allocation unknown (Acknowledged partial support).
- VKM, Norway → public risk assessment using Shibui’s company-affiliated rat study; public assessment does not remove underlying conflicts (Risk assessment; Rat author affiliations).
- NUS/NUHS, Singapore and VU Amsterdam, Netherlands → review author affiliations (Original review affiliations).
- Andrea Maier → Chi Longevity co-founder role, documented by NUHS; no glycine-review funding arrow is established (Official biography).
The sleep pilots reviewed here are concentrated in one company-connected Japanese research network. That limits independent replication and generalizability in this evidence set; it is not a judgment based on nationality. Exact research cash flows, older human-product payment terms and ultimate beneficial holdings remain unknown. PSG affiliations; Employee study; Dated holdings.
Regulation and product quality
In the United States, dietary supplements are not preapproved by FDA for effectiveness or safety in the way drugs are. A product sold with a sleep-support claim is not thereby an approved insomnia treatment. FDA overview
Japan's Foods with Function Claims system places responsibility for these claims on the food operator; it is distinct from the individually approved category. CAA scheme outline Glyna's own page also states that these products have not received government evaluation of their safety and function in that scheme. A notification number should not be presented as an independently validated clinical result.
Identity, contaminants, declared amount and batch consistency are product-quality questions. Even a valid laboratory certificate would not establish sleep effectiveness. This review did not commission testing, verify a particular retail batch or rank brands. A seller’s address, a historical factory announcement and a finished-product origin statement answer different questions (Product regulation; Historical factory role).
Frequently asked questions
Does glycine work for sleep?
There is a small commercially linked human signal. A dependable independent benefit is not established by the evidence located here. Whether an individual notices a change cannot be predicted reliably from these trials (Bias assessment; Small PSG trial; Small restriction trial).
Does it increase deep sleep?
Do not equate earlier slow-wave-sleep onset with more deep sleep. A small PSG experiment cannot support every version of that claim (Stage proportions and latency).
Is 3 g the best dose?
It is the frequently studied bedtime amount, not an established optimum. More is not proven better (Protocol; Protocol).
Is it the same as magnesium glycinate?
No. A magnesium compound and free glycine are different interventions. Read the ingredient amount and unit rather than relying on the shared word (Intervention boundary).
Can it help stress or replace melatonin?
Neither stress treatment nor equivalence to melatonin is established here. Different proposed mechanisms do not supply a head-to-head clinical result (Scope and limitations; Stress claims assigned to GABA).
Is it safe every night?
Long-term certainty is missing. The ingredient’s presence in food and the body does not prove that an added nightly dose is appropriate for every person (Safety gaps; Short exposure).
Does an industry connection mean the studies are false?
No. It means independent replication and transparent disclosure are particularly valuable. The method limitations and the funding limitations should be judged separately (Declared ties and methods; Risk of bias).
What new evidence would matter most?
A useful next step would be adequately powered, preregistered replication with clinically relevant sleep outcomes, robust blinding and systematic adverse-event follow-up. Independent financing and transparent product procurement would improve the strict independence assessment. This is a methodological recommendation from the limitations of these studies, not proof that a future trial must succeed. Pilot limitations; Small restricted-sleep study; Review limitations.
Sources and funding notes
Evidence scope: the cited primary sleep and tolerability reports, systematic review, trial registry, official safety/regulatory information and relevant financial records were examined. Original access remains incomplete for Inagawa’s 2006 subjective-sleep paper and the complete final Evins clozapine report; their abstract or indexed sections are identified explicitly. The full Yamadera, Bannai, acute-tolerability and rodent reports were read in the stated relevant sections. Review supplements and every underlying trial’s financial chain were not separately cleared. An unpublished registry entry is not a clinical result. This is a bounded evidence investigation, not an exhaustive literature or ownership audit.
Tier describes financial proximity to glycine, not whether a statement is true: 1 independent; 2 indirect ties; 3 interested party; 4 maker/seller-linked. U means unresolved and is not an independence tier. Credibility A–D is purpose-specific: A strong accountability, B useful with limitations, C materially interested, D direct commercial promotion. A company filing may document its own business accurately while its efficacy advertising remains ineligible for the verdict.
| Source | Funder, employer or revenue model; HQ country/jurisdiction | Tier / credibility | Accuracy incentive and residual limitation |
|---|---|---|---|
| Inagawa 2006 | Four Ajinomoto research/development authors plus Jikei, Japan; cash/procurement/full COI unresolved | 4 / C | Original abstract and affiliations read; complete Methods/results unavailable, secondary sample counts disagree |
| Yamadera 2007; complete original | Three Ajinomoto authors plus Jikei/Ohta, Japan; separate cash/supply terms not stated | 4 / C | Entire original main Methods/results/captions/Acknowledgments read; 11-person single-blind short trial, selected time-point findings |
| Bannai 2012 | Ajinomoto/Miyazaki, Japan; employee participants, company IRB, partial PROBRAIN; cash/material allocation unknown | 4 / C | Original methods/tables/declarations read; day-one fatigue but day-three subjective null, selected vigilance outcome |
| Soh review | NUS/NUHS Singapore and VU Netherlands; no project-funding statement; no COI declared; Maier broader clinic role separately verified | 2 + funding U / B | Original methods, sleep entries, bias and declarations read; narrative significance classification, no pooling; all trial finance not cleared |
| UMIN athlete record | Waseda sponsor, Ajinomoto funder, Japan; university registry hosts investigator-submitted data | 4 / C for protocol facts | Registration creates a checkable record; not peer-reviewed outcome evidence |
| Acute 9 g study | All authors Ajinomoto, Japan; separate cash/material transactions and full COI not stated | 4 / C | All original six pages read; 12 volunteers, open fixed sequence, seven exposure days; not long-term or rare-risk proof |
| Bannai/Kawai review; full original | Both authors Ajinomoto, Japan; separate project-cash statement absent | 4 / C | All four original pages read; mechanistic/clinical summaries, no new trial or independent replication |
| Kawai rodent study; original declarations | Three academic collaborators explicitly Ajinomoto-funded; four authors listed as employees; Japan/US | 4 / C | Relevant original methods/results and full Funding/Disclosure read; Sigma glycine named, payment and amounts unstated; rat findings stay separate |
| VKM 2016 glycine report | Norwegian public committee; NFSA commission, named experts and competence rules; individual historical financial forms not audited | 1 provisional / B for specified-dose assessment | Original scope, human/rat basis, dose calculations and conclusions read; only specified 20–650 mg/day doses, not 3 g nightly |
| Shibui rat toxicology; full original | All authors Ajinomoto Pharmaceuticals, Japan; glycine purchased from Nacalai Tesque; no COI declared, separate funding unstated | 4 / C | Original relevant methods/results/materials/declarations read; four-week male-rat NOAEL does not establish long-term human safety |
| Evins clozapine trial | MGH, US; exact funding, supplier and full individual disclosures unresolved | U / B provisional | Abstract plus primary indexed Methods/results/Discussion and clinical table read; final paper/financial footnotes not recovered; no bedtime interaction proof |
| MedlinePlus Genetics | US NLM/NIH public health information; exact page cost/full finance chain not audited | U / B for disease context | Whole official disease main read; inherited glycine accumulation, not a supplement efficacy or full independence assessment |
| NHLBI insomnia guidance | US NIH institute; budget primarily congressional appropriations per separate official record; page-specific cost not stated | 1 provisional / A for standard-care context | Whole treatment main read; CBT-I usually first for chronic insomnia; no glycine head-to-head comparison |
| NHLBI financing | US NIH institute; budget primarily, not exclusively, congressional appropriations | 1 provisional / A for stated provenance | Entire official budget-description main read; all income/donor chains and guidance cost not separately audited |
| FDA supplement guidance | US federal agency; appropriations plus user fees at agency level | 2 institutionally / A for its legal remit | Statutory accountability; political/resource constraints, no glycine efficacy assessment |
| FDA FY2026 operating plan | US federal agency; original budget authority and user-fee programs documented | 2 institutionally / A for budget facts | Actual human-food and fiscal-category tables read; not a clinical outcome or guidance-specific sponsor audit |
| Ajinomoto overview | Company headquarters Tokyo, Japan; direct product-selling interest verified separately | 4 / C for corporate facts | Whole current original profile read; March 2026 fiscal facts; full group revenues/ownership not certified |
| Ajinomoto shareholders | Same company, Japan; registered-holder table expressly dated 30 September 2025 | 4 / C for dated holdings | Whole fresh original main read; trust/custody accounts and insurers, not current ultimate beneficial ownership |
| Glyna sales page | Ajinomoto product marketing, Japan; sales revenue | 4 / D for efficacy promotion | Product-label accountability; direct selling interest; not used as benefit proof |
| Mie factory announcement | Ajinomoto corporate announcement, Japan | 4 / C for historical factory facts | Verifiable operational claim; not current batch provenance |
| Maier NUHS biography | Singapore institutional research profile; broader clinic-founder roles; exact institutional/private financing not audited | 2 / B for stated role | Official BIO text read; old course PDF unavailable, current primary replacement verifies relationship, not glycine-review funding |
| VKM governance | Norwegian public committee; secretariat administratively hosted by public-health institute | 1 provisional / B for governance process | Whole original mandate/COI/process main read; historic individual declarations and full budgets not cleared |
| CAA 2024 scheme outline | Japanese national Consumer Affairs Agency; full agency/page financial chain not audited | U / B for finite category facts | Entire one-page original scheme read; operator-responsibility category versus approval, not full current compliance or efficacy |
The reviewed clinical and safety evidence has substantial method and duration limits. Reported employer, funder and product relationships affect the strict independence grade, while unspecified cash flows remain unknown. These judgments do not prove findings false and do not certify that every relevant study or ownership relationship was located. Human review limitations; Reported financial context.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
